Trifluridine-Tipiracil with and without Bevacizumab in Colorectal Cancer - PubMed
4 hours ago
- #colorectal cancer
- #bevacizumab
- #real-world evidence
- Trifluridine-Tipiracil with Bevacizumab (FTD-TPI+bev) improved overall survival in metastatic colorectal cancer (mCRC) compared to FTD-TPI alone.
- Real-world data from the U.S. showed median overall survival (rwOS) of 8.9 months for FTD-TPI+bev vs. 5.8 months for FTD-TPI.
- Time to treatment discontinuation (rwTTD) was longer with FTD-TPI+bev (3.5 months) than FTD-TPI (2.2 months).
- Time to next treatment or death (rwTTNTD) was also longer in the FTD-TPI+bev group (4.9 months vs. 3.5 months).
- Findings support the SUNLIGHT clinical trial results, indicating FTD-TPI+bev's efficacy in mCRC.